Ketek (telithromycin) FDA Frequently Asked Questions (FAQ)-
Information provided by Dangerous Drug Attorneys
Weitz and Luxenberg is no longer accepting Ketek cases.
Ketek is an antibiotic drug used to treat very serious bacterial infections such as pneumonia and chronic bronchitis, but links have been recently found to side effects such as liver damage and death. You can read FDA frequently asked questions below regarding ketek. If you or a loved on has been injured due to ketek, you can fill out this simple form for a free case evaluation within 1 buisness day.
What is telithromycin?
Telithromycin is an FDA approved antibiotic drug, which belongs to the ketolide class, marketed in the U.S. by Aventis under the brand name Ketek. Telithromycin was approved in the U.S. in April 2004.
What is telithromycin used to treat?
Ketek (telithromycin) is indicated for the treatment of very serious bacterial infections, such as community-acquired pneumonia (including multi-drug resistant Streptococcus pneumoniae), acute bacterial sinusitis, and acute exacerbation of chronic bronchitis.
Why are the three reports described in the Annals of Internal Medicine significant?
These reports are significant due to the serious nature of the adverse events. All three patients had jaundice and abnormal liver function. One patient recovered, one required a transplant, and one died. All three patients had previously been healthy.
Did FDA know about these reports prior to this publication?
Yes.
The FDA’s MedWatch program received reports of the three serious adverse events following administration of telithromycin that were published in the Annals of Internal Medicine.
FDA has also received other reports of liver-related adverse events in patients taking telithromycin. Some of these reports were difficult to interpret because they involved patients already taking other medicines or patients with other medical conditions that might cause liver problems. In pre-marketing clinical studies, including a large safety trial, the occurrence of liver problems was infrequent and usually reversible.
What actions did FDA take regarding these reports?
The Office of Drug Safety looked at adverse events, including hepatic adverse events, in a consult in June 2005 and concluded that there was no new information that changes its assessment of the hepatic risks.
What information was known about liver problems related to telithromycin prior to approval?
Based on the pre-marketing clinical data it appeared that the risk of liver injury with telithromycin was similar to that of other marketed antibiotics.
Prior to approval, FDA looked extensively at the potential for hepatic toxicity in patients treated with Ketek. The data examined included a 25,000 patient controlled study, as well as information in nearly 4 million postmarketing prescriptions outside the United States. Ketek was the subject of two advisory committee meetings with input from a national expert on drug-induced liver disease. The committee concluded that the risk for hepatotoxicity from Ketek was similar to Augmentin and erythromycin which are other approved antibiotics.
What should patients do regarding this new information?
Patients who have been prescribed telithromycin and are not suffering side effects such as jaundice should continue taking their medicine as prescribed.
Patients who notice any yellowing of their eyes or skin or other problems like blurry vision should contact their healthcare providers.
What should healthcare providers do in response to this new information?
Healthcare providers should monitor patients taking telithromycin for signs or symptoms of liver problems. Telithromycin should be stopped in patients who develop signs or symptoms of liver problems. As with all antibiotics, telithromycin should only be used for infections by a susceptible microorganism; telithromycin is not effective on viral infections, so a patient with a viral infection who took telithromycin would be taking a risk without any benefit.
What additional actions are likely to follow?
Telithromycin is marketed and used extensively in many other countries, including Japan and countries in Europe. The FDA is working with regulatory authorities in these other countries to obtain further information on reports of liver problems associated with the use of telithromycin. While it is difficult to determine the actual frequency of adverse events from voluntary reporting systems such as the MedWatch program, FDA is continuing to work to understand better the frequency of liver-related adverse events reported for approved antibiotics, including telithromycin.
If you have suffered a liver injury while taking Ketek, fill out this simple form. A legal expert will review your potential Ketek lawsuit within 24 hours.
see also:
Ketek FAQ
Ketek Lawsuit Research - FDA Frequently Asked Questions (FAQ)Ketek (telithromycin) FDA Frequently Asked Questions FAQ
Frequently Asked Questions
Ketek Frequently Asked Questions (FAQ) from Ketek AttorneysKetek Attorney- Ketek Frequently Asked Questions (FAQ): Side Effects
